Structure-guided design of small-molecule therapeutics against RSV disease

References

• Collins PLCJ Jr. Respiratory syncytial virus and metapneumoviruses. In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott, Williams, & Wilkins; 2007. p. 1601–1645.
   Google Scholar
• Shay DK, Holman RC, Roosevelt GE, et al. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis. 2001;183:16–22. doi:10.1086/317655.
   PubMed Web of Science ®Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2095–2128. doi:10.1016/S0140-6736(12)61728-0.
   PubMed Web of Science ®Google Scholar
• Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375:1545–1555. doi:10.1016/S0140-6736(10)60206-1.
   PubMed Web of Science ®Google Scholar
• Falsey AR. Respiratory syncytial virus infection in elderly and high-risk adults. Exp Lung Res. 2005;31(Suppl 1):77.
   PubMedGoogle Scholar
• Lee N, Lui GC, Wong KT, et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin Infect Dis. 2013;57:1069–1077. doi:10.1093/cid/cit471.
   PubMed Web of Science ®Google Scholar
• DeVincenzo JP, Wilkinson T, Vaishnaw A, et al. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med. 2010;182:1305–1314. doi:10.1164/rccm.201002-0221OC.
   PubMed Web of Science ®Google Scholar
• DeVincenzo JP, El Saleeby CM, Bush AJ. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J Infect Dis. 2005;191:1861–1868. doi:10.1086/430008.
   PubMed Web of Science ®Google Scholar
• El Saleeby CM, Bush AJ, Harrison LM, et al. Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J Infect Dis. 2011;204:996–1002. doi:10.1093/infdis/jir494.
   PubMed Web of Science ®Google Scholar
• Mahadevia PJ, Malinoski FJ. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab. Arch Pediatr Adolesc Med. 2007;161:519–520. author reply 520. doi:10.1001/archpedi.161.5.519.
   PubMedGoogle Scholar
• Weiner LB, Masaquel AS, Polak MJ, et al. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States. J Med Econ. 2012;15:997–1018. doi:10.3111/13696998.2012.672942.
   PubMedGoogle Scholar
• Anderson LJ, Parker RA, Strikas RL. Association between respiratory syncytial virus outbreaks and lower respiratory tract deaths of infants and young children. J Infect Dis. 1990;161:640–646.
   PubMed Web of Science ®Google Scholar
• Groothuis JR, Woodin KA, Katz R, et al. Early ribavirin treatment of respiratory syncytial viral infection in high-risk children. J Pediatr. 1990;117:792–798.
   PubMed Web of Science ®Google Scholar
• Johnson DW. Croup. BMJ Clin Evid. 2009;2009:0321.
   PubMedGoogle Scholar
• Forster A, Maertens GN, Farrell PJ, et al. Dimerization of matrix protein is required for budding of respiratory syncytial virus. J Virol. 2015;89:4624–4635. doi:10.1128/JVI.03500-14.
   PubMed Web of Science ®Google Scholar
• DeVincenzo JP, Whitley RJ, Mackman RL, et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med. 2014;371:711–722. doi:10.1056/NEJMoa1401184.
   PubMed Web of Science ®Google Scholar
• Wang G, Deval J, Hong J, et al. Discovery of 4ʹ-chloromethyl-2ʹ-deoxy-3ʹ,5ʹ-di-O-isobutyryl-2ʹ-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. J Med Chem. 2015;58:1862–1878. doi:10.1021/jm5017279.
   PubMed Web of Science ®Google Scholar
• DeVincenzo J, Fathi H, Mcclure M, et al. Treatment with oral ALS-008176, a nucleoside analog, rapidly reduces RSV viral load and clinical disease severity in a healthy volunteer challenge study. Open Forum Infect Dis. 2014;1:S66–S69. doi:10.1093/ofid/ofu083.
   Google Scholar
• Krzyzaniak MA, Zumstein MT, Gerez JA, et al. Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein. PLoS Pathog. 2013;9:e1003309. doi:10.1371/journal.ppat.1003309.
   PubMed Web of Science ®Google Scholar
• McLellan JS, Ray WC, Peeples ME. Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol. 2013;372:83–104. doi:10.1007/978-3-642-38919-1_4.
   PubMed Web of Science ®Google Scholar
• Karron RA, Buonagurio DA, Georgiu AF, et al. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc Natl Acad Sci U S A. 1997;94:13961–13966.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Hruska J. Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein. J Virol. 1983;47:171–177.
   PubMed Web of Science ®Google Scholar
• Brindley MA, Plattet P, Plemper RK. Efficient replication of a paramyxovirus independent of full zippering of the fusion protein six-helix bundle domain. Proc Natl Acad Sci U S A. 2014;111:E3795–3804. doi:10.1073/pnas.1403609111.
   Google Scholar
• McLellan JS, Chen M, Leung S, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013;340:1113–1117. doi:10.1126/science.1234914.
   PubMed Web of Science ®Google Scholar
• Razinkov V, Gazumyan A, Nikitenko A, et al. RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein. Chem Biol. 2001;8:645–659.
   PubMed Web of Science ®Google Scholar
• Andries K, Moeremans M, Gevers T, et al. Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus. Antiviral Res. 2003;60:209–219.
   PubMed Web of Science ®Google Scholar
• Wyde PR, Chetty SN, Timmerman P, et al. Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection. Antiviral Res. 2003;60:221–231.
   PubMed Web of Science ®Google Scholar
• McKimm-Breschkin J. VP-14637 ViroPharma. Curr Opin Investig Drugs. 2000;1:425–427.
   PubMedGoogle Scholar
• Cianci C, Genovesi EV, Lamb L, et al. Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection. Antimicrob Agents Chemother. 2004;48:2448–2454. doi:10.1128/AAC.48.7.2448-2454.2004.
   PubMed Web of Science ®Google Scholar
• Douglas JL, Panis ML, Ho E, et al. Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. J Virol. 2003;77:5054–5064.
   PubMed Web of Science ®Google Scholar
• Yan D, Lee S, Thakkar VD, et al. Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors. Proc Natl Acad Sci U S A. 2014;111:E3441–3449. doi:10.1073/pnas.1405198111.
   Google Scholar
• Cianci C, Yu KL, Combrink K, et al. Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob Agents Chemother. 2004;48:413–422.
   PubMed Web of Science ®Google Scholar
• Bonfanti JF, Meyer C, Doublet F, et al. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121). J Med Chem. 2008;51:875–896. doi:10.1021/jm701284j.
   PubMed Web of Science ®Google Scholar
• Roymans D, De Bondt HL, Arnoult E, et al. Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. Proc Natl Acad Sci U S A. 2010;107:308–313. doi:10.1073/pnas.0910108106.
   PubMed Web of Science ®Google Scholar
• Battles MB, Langedijk JP, Furmanova-Hollenstein P, et al. Molecular mechanism of respiratory syncytial virus fusion inhibitors. Nat Chem Biol. 2015. doi:10.1038/nchembio.1982.
   PubMed Web of Science ®Google Scholar
• Centers for Disease C, Prevention. Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep. 2009;58:433–435.
   PubMedGoogle Scholar
• Stokes KL, Chi MH, Sakamoto K, et al. Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice. J Virol. 2011;85:5782–5793. doi:10.1128/JVI.01693-10.
   PubMed Web of Science ®Google Scholar
• Yan D, Weisshaar M, Lamb K, et al. Replication-competent influenza virus and respiratory syncytial virus luciferase reporter strains engineered for co-infections identify antiviral compounds in combination screens. Biochemistry. 2015;54:5589–5604. doi:10.1021/acs.biochem.5b00623.
   PubMed Web of Science ®Google Scholar
• Grosfeld H, Hill MG, Collins PL. RNA replication by respiratory syncytial virus (RSV) is directed by the N, P, and L proteins; transcription also occurs under these conditions but requires RSV superinfection for efficient synthesis of full-length mRNA. J Virol. 1995;69:5677–5686.
   PubMed Web of Science ®Google Scholar
• Yu Q, Hardy RW, Wertz GW. Functional cDNA clones of the human respiratory syncytial (RS) virus N, P, and L proteins support replication of RS virus genomic RNA analogs and define minimal trans-acting requirements for RNA replication. J Virol. 1995;69:2412–2419.
   PubMed Web of Science ®Google Scholar
• Collins PL, Hill MG, Camargo E, et al. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5ʹ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci U S A. 1995;92:11563–11567.
   PubMed Web of Science ®Google Scholar
• Bakker SE, Duquerroy S, Galloux M, et al. The respiratory syncytial virus nucleoprotein-RNA complex forms a left-handed helical nucleocapsid. J Gen Virol. 2013;94:1734–1738. doi:10.1099/vir.0.053025-0.
   PubMed Web of Science ®Google Scholar
• Liljeroos L, Krzyzaniak MA, Helenius A, et al. Architecture of respiratory syncytial virus revealed by electron cryotomography. Proc Natl Acad Sci U S A. 2013. doi:10.1073/pnas.1309070110.
   PubMed Web of Science ®Google Scholar
• Tawar RG, Duquerroy S, Vonrhein C, et al. Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus. Science. 2009;326:1279–1283. doi:10.1126/science.1177634.
   PubMed Web of Science ®Google Scholar
• El Omari K, Dhaliwal B, Ren J, et al. Structures of respiratory syncytial virus nucleocapsid protein from two crystal forms: details of potential packing interactions in the native helical form. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011;67:1179–1183. doi:10.1107/S1744309111029228.
   PubMedGoogle Scholar
• Khattar SK, Yunus AS, Samal SK. Mapping the domains on the phosphoprotein of bovine respiratory syncytial virus required for N-P and P-L interactions using a minigenome system. J Gen Virol. 2001;82:775–779. doi:10.1099/0022-1317-82-4-775.
   PubMed Web of Science ®Google Scholar
• Garcia J, Garcia-Barreno B, Vivo A, et al. Cytoplasmic inclusions of respiratory syncytial virus-infected cells: formation of inclusion bodies in transfected cells that coexpress the nucleoprotein, the phosphoprotein, and the 22 K protein. Virology. 1993;195:243–247. doi:10.1006/viro.1993.1366.
   PubMed Web of Science ®Google Scholar
• Oliveira AP, Simabuco FM, Tamura RE, et al. Human respiratory syncytial virus N, P and M protein interactions in HEK-293T cells. Virus Res. 2013;177:108–112. doi:10.1016/j.virusres.2013.07.010.
   PubMed Web of Science ®Google Scholar
• Kingston RL, Hamel DJ, Gay LS, et al. Structural basis for the attachment of a paramyxoviral polymerase to its template. Proc Natl Acad Sci U S A. 2004;101:8301–8306. doi:10.1073/pnas.0402690101.
   PubMed Web of Science ®Google Scholar
• Cox R, Pickar A, Qiu S, et al. Structural studies on the authentic mumps virus nucleocapsid showing uncoiling by the phosphoprotein. Proc Natl Acad Sci U S A. 2014;111:15208–15213. doi:10.1073/pnas.1413268111.
   PubMed Web of Science ®Google Scholar
• Yabukarski F, Lawrence P, Tarbouriech N, et al. Structure of Nipah virus unassembled nucleoprotein in complex with its viral chaperone. Nat Struct Mol Biol. 2014;21. doi:10.1038/nsmb.2868.
   PubMed Web of Science ®Google Scholar
• Llorente MT, Garcia-Barreno B, Calero M, et al. Structural analysis of the human respiratory syncytial virus phosphoprotein: characterization of an alpha-helical domain involved in oligomerization. J Gen Virol. 2006;87:159–169. doi:10.1099/vir.0.81430-0.
   PubMed Web of Science ®Google Scholar
• Karlin D, Ferron F, Canard B, et al. Structural disorder and modular organization in Paramyxovirinae N and P. J Gen Virol. 2003;84:3239–3252. doi:10.1099/vir.0.19451-0.
   PubMed Web of Science ®Google Scholar
• Cox R, Green TJ, Purushotham S, et al. Structural and functional characterization of the mumps virus phosphoprotein. J Virol. 2013;87:7558–7568. doi:10.1128/JVI.00653-13.
   PubMed Web of Science ®Google Scholar
• Bruhn JF, Barnett KC, Bibby J, et al. Crystal structure of the nipah virus phosphoprotein tetramerization domain. J Virol. 2014;88:758–762. doi:10.1128/JVI.02294-13.
   PubMed Web of Science ®Google Scholar
• Ouizougun-Oubari M, Pereira N, Tarus B, et al. A druggable pocket at the nucleocapsid/phosphoprotein interaction site of human respiratory syncytial virus. J Virol. 2015;89:11129–11143. doi:10.1128/JVI.01612-15.
   PubMed Web of Science ®Google Scholar
• Leyrat C, Renner M, Harlos K, et al. Solution and crystallographic structures of the central region of the phosphoprotein from human metapneumovirus. PLoS One. 2013;8:e80371. doi:10.1371/journal.pone.0080371.
   Google Scholar
• Galloux M, Gabiane G, Sourimant J, et al. Identification and characterization of the binding site of the respiratory syncytial virus phosphoprotein to RNA-free nucleoprotein. J Virol. 2015;89:3484–3496. doi:10.1128/JVI.03666-14.
   PubMed Web of Science ®Google Scholar
• Kolakofsky D, Le Mercier P, Iseni F, et al. Viral DNA polymerase scanning and the gymnastics of Sendai virus RNA synthesis. Virology. 2004;318:463–473.
   PubMed Web of Science ®Google Scholar
• Galloux M, Tarus B, Blazevic I, et al. Characterization of a viral phosphoprotein binding site on the surface of the respiratory syncytial nucleoprotein. J Virol. 2012;86:8375–8387. doi:10.1128/JVI.00058-12.
   PubMed Web of Science ®Google Scholar
• Kingston RL, Baase WA, Gay LS. Characterization of nucleocapsid binding by the measles virus and mumps virus phosphoproteins. J Virol. 2004;78:8630–8640. doi:10.1128/JVI.78.16.8630-8640.2004.
   PubMed Web of Science ®Google Scholar
• Collins PL, Hill MG, Cristina J, et al. Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus. Proc Natl Acad Sci U S A. 1996;93:81–85.
   PubMed Web of Science ®Google Scholar
• Hardy RW, Wertz GW. The product of the respiratory syncytial virus M2 gene ORF1 enhances readthrough of intergenic junctions during viral transcription. J Virol. 1998;72:520–526.
   PubMed Web of Science ®Google Scholar
• Asenjo A, Calvo E, Villanueva N. Phosphorylation of human respiratory syncytial virus P protein at threonine 108 controls its interaction with the M2-1 protein in the viral RNA polymerase complex. J Gen Virol. 2006;87:3637–3642. doi:10.1099/vir.0.82165-0.
   PubMed Web of Science ®Google Scholar
• Mason SW, Aberg E, Lawetz C, et al. Interaction between human respiratory syncytial virus (RSV) M2-1 and P proteins is required for reconstitution of M2-1-dependent RSV minigenome activity. J Virol. 2003;77:10670–10676.
   PubMed Web of Science ®Google Scholar
• Cartee TL, Wertz GW. Respiratory syncytial virus M2-1 protein requires phosphorylation for efficient function and binds viral RNA during infection. J Virol. 2001;75:12188–12197. doi:10.1128/JVI.75.24.12188-12197.2001.
   PubMed Web of Science ®Google Scholar
• Tanner SJ, Ariza A, Richard CA, et al. Crystal structure of the essential transcription antiterminator M2-1 protein of human respiratory syncytial virus and implications of its phosphorylation. Proc Natl Acad Sci U S A. 2014;111:1580–1585. doi:10.1073/pnas.1317262111.
   PubMed Web of Science ®Google Scholar
• Blondot ML, Dubosclard V, Fix J, et al. Structure and functional analysis of the RNA- and viral phosphoprotein-binding domain of respiratory syncytial virus M2-1 protein. PLoS Pathog. 2012;8:e1002734. doi:10.1371/journal.ppat.1002734.
   Google Scholar
• Cancellieri M, Bassetto M, Widjaja I, et al. In silico structure-based design and synthesis of novel anti-RSV compounds. Antiviral Res. 2015;122:46–50. doi:10.1016/j.antiviral.2015.08.003.
   PubMed Web of Science ®Google Scholar
• Hamaguchi M, Yoshida T, Nishikawa K, et al. Transcriptive complex of Newcastle disease virus. I. Both L and P proteins are required to constitute an active complex. Virology. 1983;128:105–117.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Mathur M, Banerjee AK. Unique capping activity of the recombinant RNA polymerase (L) of vesicular stomatitis virus: association of cellular capping enzyme with the L protein. Biochem Biophys Res Commun. 2002;293:264–268. doi:10.1016/S0006-291X(02)00217-6.
   PubMed Web of Science ®Google Scholar
• Ogino T, Kobayashi M, Iwama M, et al. Sendai virus RNA-dependent RNA polymerase L protein catalyzes cap methylation of virus-specific mRNA. J Biol Chem. 2005;280:4429–4435. doi:10.1074/jbc.M411167200.
   PubMed Web of Science ®Google Scholar
• Poch O, Blumberg BM, Bougueleret L, et al. Sequence comparison of five polymerases (L proteins) of unsegmented negative-strand RNA viruses: theoretical assignment of functional domains. J Gen Virol. 1990;71(Pt 5):1153–1162. doi:10.1099/0022-1317-71-5-1153.
   PubMed Web of Science ®Google Scholar
• Svenda M, Berg M, Moreno-Lopez J, et al. Analysis of the large (L) protein gene of the porcine rubulavirus LPMV: identification of possible functional domains. Virus Res. 1997;48:57–70.
   PubMed Web of Science ®Google Scholar
• Dochow M, Krumm SA, Crowe JE Jr., et al. Independent structural domains in the paramyxovirus polymerase protein. J Biol Chem. 2012. doi:10.1074/jbc.M111.325258.
   PubMed Web of Science ®Google Scholar
• Duprex WP, Collins FM, Rima BK. Modulating the function of the measles virus RNA-dependent RNA polymerase by insertion of green fluorescent protein into the open reading frame. J Virol. 2002;76:7322–7328.
   PubMed Web of Science ®Google Scholar
• Brown DD, Rima BK, Allen IV, et al. Rational attenuation of a morbillivirus by modulating the activity of the RNA-dependent RNA polymerase. J Virol. 2005;79:14330–14338. doi:10.1128/JVI.79.22.14330-14338.2005.
   PubMed Web of Science ®Google Scholar
• Liang B, Li Z, Jenni S, et al. Structure of the L protein of vesicular stomatitis virus from electron cryomicroscopy. Cell. 2015;162:314–327. doi:10.1016/j.cell.2015.06.018.
   PubMed Web of Science ®Google Scholar
• Cevik B, Holmes DE, Vrotsos E, et al. The phosphoprotein (P) and L binding sites reside in the N-terminus of the L subunit of the measles virus RNA polymerase. Virology. 2004;327:297–306. doi:10.1016/j.virol.2004.07.002.
   PubMed Web of Science ®Google Scholar
• Cevik B, Smallwood S, Moyer SA. The L-L oligomerization domain resides at the very N-terminus of the sendai virus L RNA polymerase protein. Virology. 2003;313:525–536.
   PubMed Web of Science ®Google Scholar
• Holmes DE, Moyer SA. The phosphoprotein (P) binding site resides in the N terminus of the L polymerase subunit of sendai virus. J Virol. 2002;76:3078–3083.
   PubMed Web of Science ®Google Scholar
• Horikami SM, Smallwood S, Bankamp B, et al. An amino-proximal domain of the L protein binds to the P protein in the measles virus RNA polymerase complex. Virology. 1994;205:540–545. doi:10.1006/viro.1994.1676.
   PubMed Web of Science ®Google Scholar
• Smallwood S, Moyer SA. The L polymerase protein of parainfluenza virus 3 forms an oligomer and can interact with the heterologous Sendai virus L, P and C proteins. Virology. 2004;318:439–450. doi:10.1016/j.virol.2003.09.045.
   PubMed Web of Science ®Google Scholar
• Malur AG, Gupta NK, De Bishnu P, et al. Analysis of the mutations in the active site of the RNA-dependent RNA polymerase of human parainfluenza virus type 3 (HPIV3). Gene Expr. 2002;10:93–100.
   PubMed Web of Science ®Google Scholar
• Ogino T, Banerjee AK. Unconventional mechanism of mRNA capping by the RNA-dependent RNA polymerase of vesicular stomatitis virus. Mol Cell. 2007;25:85–97. doi:10.1016/j.molcel.2006.11.013.
   PubMed Web of Science ®Google Scholar
• Gopinath M, Shaila MS. RNA triphosphatase and guanylyl transferase activities are associated with the RNA polymerase protein L of rinderpest virus. J Gen Virol. 2009;90:1748–1756. doi:10.1099/vir.0.010975-0.
   PubMed Web of Science ®Google Scholar
• Ferron F, Longhi S, Henrissat B, et al. Viral RNA-polymerases – a predicted 2ʹ-O-ribose methyltransferase domain shared by all Mononegavirales. Trends Biochem Sci. 2002;27:222–224.
   PubMed Web of Science ®Google Scholar
• Paesen GC, Collet A, Sallamand C, et al. X-ray structure and activities of an essential Mononegavirales L-protein domain. Nat Commun. 2015;6:8749. doi:10.1038/ncomms9749.
   PubMed Web of Science ®Google Scholar
• Issur M, Picard-Jean F, Bisaillon M. The RNA capping machinery as an anti-infective target. Wiley Interdiscip Rev RNA. 2011;2:184–192. doi:10.1002/wrna.43.
   PubMed Web of Science ®Google Scholar
• Murphy AM, Grdzelishvili VZ. Identification of sendai virus L protein amino acid residues affecting viral mRNA cap methylation. J Virol. 2009;83:1669–1681. doi:10.1128/JVI.01438-08.
   PubMed Web of Science ®Google Scholar
• Lim SV, Rahman MB, Tejo BA. Structure-based and ligand-based virtual screening of novel methyltransferase inhibitors of the dengue virus. BMC Bioinformatics. 2011;12(Suppl 13):S24. doi:10.1186/1471-2105-12-S13-S24.
   Google Scholar
• De Clercq E, Neyts J. Antiviral agents acting as DNA or RNA chain terminators. Handb Exp Pharmacol. 2009;189:53–84.
   PubMedGoogle Scholar
• Soriano V, Vispo E, De Mendoza C, et al. Hepatitis C therapy with HCV NS5B polymerase inhibitors. Expert Opin Pharmacother. 2013;14:1161–1170. doi:10.1517/14656566.2013.795543.
   PubMed Web of Science ®Google Scholar
• Wright PJ, Crameri G, Eaton BT. RNA synthesis during infection by Hendra virus: an examination by quantitative real-time PCR of RNA accumulation, the effect of ribavirin and the attenuation of transcription. Arch Virol. 2005;150:521–532. doi:10.1007/s00705-004-0417-5.
   PubMed Web of Science ®Google Scholar
• Crotty S, Andino R. Implications of high RNA virus mutation rates: lethal mutagenesis and the antiviral drug ribavirin. Microbes Infect. 2002;4:1301–1307.
   PubMed Web of Science ®Google Scholar
• Gilbert BE, Knight V. Biochemistry and clinical applications of ribavirin. Antimicrob Agents Chemother. 1986;30:201–205.
   PubMed Web of Science ®Google Scholar
• Furuta Y, Takahashi K, Fukuda Y, et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother. 2002;46:977–981.
   PubMed Web of Science ®Google Scholar
• Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013;100:446–454. doi:10.1016/j.antiviral.2013.09.015.
   PubMed Web of Science ®Google Scholar
• Deval J, Hong J, Wang G, et al. Molecular basis for the selective inhibition of respiratory syncytial virus RNA polymerase by 2ʹ-fluoro-4ʹ-chloromethyl-cytidine triphosphate. PLoS Pathog. 2015;11:e1004995. doi:10.1371/journal.ppat.1004995.
   PubMed Web of Science ®Google Scholar
• Laganas VA, Dunn EF, McLaughlin RE, et al. Characterization of novel respiratory syncytial virus inhibitors identified by high throughput screen. Antiviral Res. 2014;115C:71–74.
   Google Scholar
• De Bethune MP. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Res. 2010;85:75–90. doi:10.1016/j.antiviral.2009.09.008.
   PubMed Web of Science ®Google Scholar
• Basavapathruni A, Anderson KS. Reverse transcription of the HIV-1 pandemic. FASEB J. 2007;21:3795–3808.
   PubMed Web of Science ®Google Scholar
• Usach I, Melis V, Peris JE. Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. J Int AIDS Soc. 2013;16:1–14.
   PubMed Web of Science ®Google Scholar
• Das K, Clark AD Jr., Lewi PJ, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem. 2004;47:2550–2560. doi:10.1021/jm030558s.
   PubMed Web of Science ®Google Scholar
• Matharu DS, Flaherty DP, Simpson DS, et al. Optimization of potent and selective quinazolinediones: inhibitors of respiratory syncytial virus that block RNA-dependent RNA-polymerase complex activity. J Med Chem. 2014;57:10314–10328. doi:10.1021/jm500902x.
   PubMed Web of Science ®Google Scholar
• Liuzzi M, Mason SW, Cartier M, et al. Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNA-dependent RNA polymerase. J Virol. 2005;79:13105–13115. doi:10.1128/JVI.79.20.13105-13115.2005.
   PubMed Web of Science ®Google Scholar
• Tiong-Yip CL, Aschenbrenner L, Johnson KD, et al. Characterization of a respiratory syncytial virus L protein inhibitor. Antimicrob Agents Chemother. 2014;58:3867–3873. doi:10.1128/AAC.02540-14.
   PubMed Web of Science ®Google Scholar
• Yoon JJ, Krumm SA, Ndungu JM, et al. Target analysis of the experimental measles therapeutic AS-136A. Antimicrob Agents Chemother. 2009;53:3860–3870. doi:10.1128/AAC.00503-09.
   PubMed Web of Science ®Google Scholar
• Hwang H, Vreven T, Janin J, et al. Protein-protein docking benchmark version 4.0. Proteins. 2010;78:3111–3114. doi:10.1002/prot.22830.
   PubMed Web of Science ®Google Scholar
• Arkin MR, Tang Y, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. Chem Biol. 2014;21:1102–1114. doi:10.1016/j.chembiol.2014.09.001.
   PubMed Web of Science ®Google Scholar
• Labbe CM, Laconde G, Kuenemann MA, et al. iPPI-DB: a manually curated and interactive database of small non-peptide inhibitors of protein-protein interactions. Drug Discov Today. 2013;18:958–968. doi:10.1016/j.drudis.2013.05.003.
   PubMed Web of Science ®Google Scholar
• Basse MJ, Betzi S, Bourgeas R, et al. 2P2Idb: a structural database dedicated to orthosteric modulation of protein-protein interactions. Nucleic Acids Res. 2013;41:D824–827. doi:10.1093/nar/gks1002.
   PubMed Web of Science ®Google Scholar
• Higueruelo AP, Schreyer A, Bickerton GR, et al. Atomic interactions and profile of small molecules disrupting protein-protein interfaces: the TIMBAL database. Chem Biol Drug Des. 2009;74:457–467. doi:10.1111/j.1747-0285.2009.00889.x.
   PubMed Web of Science ®Google Scholar
• Smith MC, Gestwicki JE. Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity. Expert Rev Mol Med. 2012;14:e16. doi:10.1017/erm.2012.10.
   PubMed Web of Science ®Google Scholar
• Chapman J, Abbott E, Alber DG, et al. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother. 2007;51:3346–3353. doi:10.1128/AAC.00211-07.
   PubMed Web of Science ®Google Scholar
• Challa S, Scott AD, Yuzhakov O, et al. Mechanism of action for respiratory syncytial virus inhibitor RSV604. Antimicrob Agents Chemother. 2015;59:1080–1087. doi:10.1128/AAC.04119-14.
   PubMed Web of Science ®Google Scholar
• Marty F 2007. A double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of RSV604 in adults with respiratory syncytial virus infection following stem cell transplantation. IXth International Symposium on Respiratory Viral Infections, Causeway Bay, Hong Kong, 2007 Mar 3–6.
   Google Scholar
• Mackman RL, Sangi M, Sperandio D, et al. Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem. 2015;58:1630–1643. doi:10.1021/jm5017768.
   PubMed Web of Science ®Google Scholar
• DeVincenzo JP, McClure MW, Symons JA, et al. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med. 2015;373:2048–2058. doi:10.1056/NEJMoa1413275.
   PubMed Web of Science ®Google Scholar
• Dent J, Grieve S, Harland R, et al. 2005. Multiple-dose safety and pharmacokinetics of A-60444, a novel compound active against respiratory syncytial virus (RSV). 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC.
   Google Scholar
• Weiss WJ, Murphy T, Lynch ME, et al. Inhalation efficacy of RFI-641 in an African green monkey model of RSV infection. J Med Primatol. 2003;32:82–88.
   PubMed Web of Science ®Google Scholar
• Yu KL, Sin N, Civiello RL, et al. Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability. Bioorg Med Chem Lett. 2007;17:895–901. doi:10.1016/j.bmcl.2006.11.063.
   PubMed Web of Science ®Google Scholar
• Safety Study of Oral BTA9881 to Treat RSV Infection. Biota Scientific Management Pty Ltd. U.S. National Institutes of Health. 2007. Available from: https://clinicaltrials.gov/ct2/show/NCT00504907.
   Google Scholar
• Ispas G, Koul A, Verbeeck J, et al. Antiviral activity of TMC353121, a Respiratory Syncytial Virus (RSV) fusion inhibitor, in a non-human primate model. PLoS One. 2015;10:e0126959. doi:10.1371/journal.pone.0126959.
   PubMed Web of Science ®Google Scholar
• A Trial to Assess the Safety, Tolerability and Pharmacokinetics of MDT-637 in Healthy Volunteers. MicroDose Therapeutx, Inc. U.S. National Institute of Health. 2012. Available from: https://clinicaltrials.gov/ct2/show/NCT01489306.
   Google Scholar